As­traZeneca, Mer­ck win red car­pet treat­ment at the FDA as a 3-time los­er seeks speedy OK for rare tu­mors

As­traZeneca’s R&D group doesn’t take fail­ure ly­ing down.

Hit with piv­otal set­backs for their MEK 1/2 in­hibitor selume­tinib in sev­er­al can­cer stud­ies, they re­grouped and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER